Objective: To report pharmacokinetic alterations and optimal dosing of piperacillin/
tazobactam in an obese patient. Case Summary: A 39-year-old morbidly obese (weight 167 …

The study objective was to evaluate the population pharmacokinetics and
pharmacodynamics of piperacillin and tazobactam administered by prolonged infusion in …

The study objective was to evaluate steady-state pharmacokinetics and pharmacodynamics
of piperacillin and tazobactam administered by prolonged infusion in obese patients …

Study Objective To evaluate the steady‐state pharmacokinetic and pharmacodynamic
parameters of piperacillin in morbidly obese, surgical intensive care patients. Design Open …

Abstract Background and Objective Standard piperacillin–tazobactam (PT) dosing may be
suboptimal in obesity, but high-dose regimens have not been studied. We prospectively …

The treatment of infections in critically ill obese and morbidly obese patients is challenging
because of the combined physiological changes that result from obesity and critical illness …

Study Objective. To compare the pharmacokinetic and pharmacodynamic profiles of two
dosing regimens for piperacillin‐tazobactam against commonly encountered pathogens …

Objective: Obesity and critical illness modify pharmacokinetics of antibiotics, but piperacillin-
tazobactam continuous IV infusion pharmacokinetics has been poorly studied in obese …

Study Objective. To determine the appropriate compartmental and noncompartmental
pharmacokinetic parameters for intravenous piperacillin and tazobactam. Design …

Piperacillin/tazobactam is a new combination of a broad-spectrum penicillin and a beta-
lactamase inhibitor. In studies in healthy volunteers, the pharmacokinetics of piperacillin …